INCAGN-1949
- Generic Name
- INCAGN-1949
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1
Completed
- Conditions
- Advanced Malignancies
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Incyte Biosciences International Sàrl
- Target Recruit Count
- 52
- Registration Number
- NCT03241173
- Locations
- 🇺🇸
The University of Alabama Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸Mount Sinai Medical Center of Florida, Inc., Miami, Florida, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Incyte Biosciences International Sàrl
- Target Recruit Count
- 87
- Registration Number
- NCT02923349
- Locations
- 🇺🇸
Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇨🇭University Hospital of Laussane (CHUV), Lausanne, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath